CohBar, Inc.

The momentum for this stock is not very good. CohBar, Inc. is not very popular among insiders. CohBar, Inc. is a mediocre stock to choose.
Log in to see more information.
CohBar, Inc. engages in the research and development of mitochondria-based therapeutics. It focuses...
CWBR Fundamental Data by TradingView

News

CohBar (NASDAQ:CWBR) Shares Down 1.3%
CohBar (NASDAQ:CWBR) Shares Down 1.3%

Zolmax CohBar, Inc. (NASDAQ:CWBR Get Free Report)s share price dropped 1.3% on Tuesday . The stock traded as low as $0.74 and last traded at $0.77. Approximately 93,161 shares traded hands...\n more…

Why CohBar (CWBR) Stock Is Down Nearly 50% Today
Why CohBar (CWBR) Stock Is Down Nearly 50% Today

Benzinga CohBar Inc (NASDAQ: CWBR) shares are trading lower by 47% to $0.92 Wednesday afternoon.\n more…

CohBar Reports Second Quarter 2023 Financial Results
CohBar Reports Second Quarter 2023 Financial Results

Globe Newswire MENLO PARK, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023. Second Quarter 2023 Summary and Financial Results Entered into Definitive Merger Agreement with Morphogenesis: In May 2023...\n more…

CohBar's Acquisition Partner Touts Encouraging Data From Personalized Cancer Vaccine
CohBar's Acquisition Partner Touts Encouraging Data From Personalized Cancer Vaccine

Benzinga The ongoing Phase 1b study evaluates IFx-Hu2.0 in a two-stage study design to assess the safety and to examine the effects of repeated weekly dosing for up to 3 weeks on the magnitude of the ensuing systemic immune response to determine the optimal dose and schedule for a planned Phase 2/3 registration directed trial.\n more…

Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Ca
Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Ca

Globe Newswire IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5 of 7 (71%) of patients achieved durable systemic anti-tumor responses following IFx-Hu2.0 therapy and rechallenge with an immune checkpoint inhibitor (ICI) in patients who exhibited primary resistance to ICIs ...\n more…

COHBAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of CohBar, Inc. - CWBR
COHBAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of CohBar, Inc. - CWBR

Business Wire Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed merger of CohBar, Inc. (the Company) (NasdaqCM: CWBR) with Morphogenesis, Inc. pursuant to which CohBar shareholders will end up owning...\n more…